Brain Scans and Eye Tests for Early Alzheimer's Changes in Older Adults
Studies brain and pupil markers in healthy older adults to understand early Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk
Key facts
- Where
- Toulouse, FranceSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 100 years old?
Source: NCT07007208, who can take part
Where in France
- University Hospital of ToulouseToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT07007208EU 2023-507668-38-00
- Record updated
- 17 July 2026
- Original description
Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be assessed in vivo with MRI and pupil measures. The current research proposes to evaluate these LC markers in an aged healthy cohort (n=100, with half APOE4 positive) and to relate these markers with cerebral tau pathology, AD risk and cognitive function.Read full original descriptionShow less
Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk.
Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be assessed in vivo with MRI and pupil measures. The current research proposes to evaluate these LC markers in an aged healthy cohort (n=100, with half APOE4 positive) and to relate these markers with cerebral tau pathology, AD risk and cognitive function.
Inclusion: Participant in the INSPIRE-T cohort; Normal cognitive assessment; MMSE score ≥ 27 out of 30 (Mini-Mental State Examination); Normal visual abilities (in corrected or uncorrected vision); Normal motor skills.
Exclusion: Subjects with a psychiatric disorder and a PHQ-9 score > 10 or under treatment with NRI; Subjects with a known allergic reaction to the PET radiopharmaceutical ([18F] Flortaucipir) or any of its excipients; Subjects with a neurodegenerative condition or a history of cerebral ischemia; Subjects with a contraindication to MRI exam; Subjects with an ophthalmological pathology making oculometric measurements difficult.